(E) [IL2-1] Renin angiotensin in health and aging
【略歴】
"Dr. Victor J. Dzau was appointed chancellor for health aff airs at Duke University and president and CEO of the Duke University Health System eff ective July 1, 2004. He is also James B. Duke Professor of Medicine and director of molecular and genomic vascular biology.
Before coming to Duke, Dzau was the Hersey Professor of the Theory and Practice of Physic (Medicine) at Harvard Medical School, and held the positions of chairman of the Department of Medicine, and physician-inchief and director of research at Brigham and Women's Hospital, Boston. Prior to this, he served as Arthur Bloomfi eld Professor and chairman of the Department of Medicine at Stanford University.
Dzau's academic interests are in cardiovascular translational research and mission-based education. He pioneered gene therapy for vascular disease, being the first to introduce DNA decoy molecules to block transcriptions as gene therapy in vivo. Two of his discoveries, E2F decoy and nitric oxide synthase gene therapy, are now being evaluated in clinical trials.
Dzau received the first Hatter Award from the Medical Research Council of South Africa in 2000. He was awarded the Gustav Nylin Medal by the Swedish Royal College of Medicine and the Swedish Cardiology Society; the Novartis Award for Hypertension Research by the American Heart Association (which also named him one of its distinguished scientists for 2004); the 2004 Max Delbruck Medal by the Max Delbruck Center for Molecular Medicine, Berlin; the 2005 Golden Door Award by the International Institute of Boston; a 2005 Ellis Island Medal of Honor by the National Ethnic Coalition of Organizations, and the 2006 Robert H. Williams, MD, Award by the Association of Professors of Medicine.
Dzau earned his undergraduate and medical degrees from McGill University in Montreal, Canada."
"Dr. Victor J. Dzau was appointed chancellor for health aff airs at Duke University and president and CEO of the Duke University Health System eff ective July 1, 2004. He is also James B. Duke Professor of Medicine and director of molecular and genomic vascular biology.
Before coming to Duke, Dzau was the Hersey Professor of the Theory and Practice of Physic (Medicine) at Harvard Medical School, and held the positions of chairman of the Department of Medicine, and physician-inchief and director of research at Brigham and Women's Hospital, Boston. Prior to this, he served as Arthur Bloomfi eld Professor and chairman of the Department of Medicine at Stanford University.
Dzau's academic interests are in cardiovascular translational research and mission-based education. He pioneered gene therapy for vascular disease, being the first to introduce DNA decoy molecules to block transcriptions as gene therapy in vivo. Two of his discoveries, E2F decoy and nitric oxide synthase gene therapy, are now being evaluated in clinical trials.
Dzau received the first Hatter Award from the Medical Research Council of South Africa in 2000. He was awarded the Gustav Nylin Medal by the Swedish Royal College of Medicine and the Swedish Cardiology Society; the Novartis Award for Hypertension Research by the American Heart Association (which also named him one of its distinguished scientists for 2004); the 2004 Max Delbruck Medal by the Max Delbruck Center for Molecular Medicine, Berlin; the 2005 Golden Door Award by the International Institute of Boston; a 2005 Ellis Island Medal of Honor by the National Ethnic Coalition of Organizations, and the 2006 Robert H. Williams, MD, Award by the Association of Professors of Medicine.
Dzau earned his undergraduate and medical degrees from McGill University in Montreal, Canada."